Odyssey Therapeutics, Inc. (ODTX): Results of Operations and Financial Condition
Odyssey Therapeutics, Inc. (ODTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001882782 0001882782 2026-08-04 2026-08-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04
How this was made
The 30-second read
Why it matters
The filing itself is a procedural disclosure that points to the actual earnings content in Exhibit 99.1. Without the exhibit’s figures, the only actionable takeaway is that a new quarterly results package is now available and can be used to reassess valuation, cash runway, and expectations.
Market read
Traders should treat this as the start of the earnings-information window for ODTX, with the real trading signal likely contained in Exhibit 99.1.
What to watch
Traders should focus on cash balance, operating expenses, and any pipeline or financing language in Exhibit 99.1, since those are often the true drivers for biotech 8-K earnings reactions.
Background
The SEC Form 8-K (Item 2.02) indicates Odyssey Therapeutics announced quarterly financial results for the three months ended June 30, 2026 and furnished a press release as Exhibit 99.1.
Ticker impact
Odyssey Therapeutics filed an 8-K stating it announced financial results for the three months ended June 30, 2026, with Exhibit 99.1 furnished.
Potentially volatile around the release of Exhibit 99.1 details, but direction depends on the specific results and any guidance included there.
The 8-K itself confirms the results announcement and that the press release is attached as Exhibit 99.1, but the scraped text does not include the actual numbers or guidance.
Market effects
Biopharma small-cap sentiment can shift on quarterly cash burn, runway, and any updates to pipeline milestones, but no such details are present in the scraped text.
Primarily impacts US small-cap biotech sentiment; no cross-market macro linkage is disclosed.
Limited global relevance unless the attached Exhibit 99.1 includes major regulatory or partnership updates, which are not shown here.
Counterpoint
If Exhibit 99.1 contains no material surprises (typical burn and no guidance changes), the filing may have limited incremental impact beyond routine quarterly reporting.
Key entities
- issuerOdyssey Therapeutics, Inc.
Subject of the 8-K, filed to report results of operations and financial condition for the quarter ended June 30, 2026.
- filingSEC Form 8-K
Current report under Item 2.02, furnishing the quarterly results press release as Exhibit 99.1.
